518A2
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
518A2
|
EC50 |
|
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 518A2 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
8505C
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
Cytotoxicity against human 8505C cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
8505C
|
EC50 |
|
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human 8505C cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
A2780
|
EC50 |
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
A2780
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
Cytotoxicity against human A2780 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
A2780
|
EC50 |
|
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A2780 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910]
|
A2780
|
EC50 |
|
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A2780 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
A-375
|
EC50 |
|
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human A375 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910]
|
A549
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
Antiproliferative activity against human A549 cells harbouring wild type EGFR incubated for 72 hrs by SRB assay
|
[PMID: 31718182]
|
A549
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631]
|
A549
|
IC50 |
> 100 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
A549
|
IC50 |
|
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human A549 cells assessed as drug level causing decrease in calcein fluorescence
|
[PMID: 19200744]
|
A549
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
Cytotoxicity against human A549 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
A549
|
IC50 |
10.249 μM
Compound: Hederagenin
|
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662]
|
A549
|
EC50 |
|
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human A549 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
A549
|
IC50 |
|
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human A549 cells after 48 hrs by resazurin reduction test
|
[PMID: 19200744]
|
AGS
|
IC50 |
36.14 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human AGS cells after 72 hrs by MTT assay
Antiproliferative activity against human AGS cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
BC
|
IC50 |
> 5 μg/mL
Compound: Hederagenin
|
Cytotoxicity against human BC cells by colorimetric method
Cytotoxicity against human BC cells by colorimetric method
|
[PMID: 16038539]
|
BGC-823
|
IC50 |
52.07 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
Antiproliferative activity against human BGC823 cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
DLD-1
|
IC50 |
|
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
Cytotoxicity against human DLD1 cells after 48 hrs by resazurin reduction test
|
[PMID: 19200744]
|
DLD-1
|
IC50 |
|
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
Cell membrane permeabilization in human DLD1 cells assessed as drug level causing decrease in calcein fluorescence
|
[PMID: 19200744]
|
FaDu
|
EC50 |
|
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
FaDu
|
EC50 |
|
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human FADU cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910]
|
HeLa
|
IC50 |
|
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
HeLa
|
IC50 |
53.96 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
HepG2
|
CC50 |
|
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
Cytotoxicity in human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
[PMID: 29024910]
|
HepG2
|
IC50 |
|
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
Inhibition of TNF-alpha-induced NFkappaB activation in human HepG2 cells after 1 hr by luciferase reporter assay
|
[PMID: 21870831]
|
HepG2
|
IC50 |
|
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
HL-60
|
IC50 |
|
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human HL60 cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|
HT-29
|
EC50 |
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
HT-29
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
HT-29
|
EC50 |
|
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910]
|
HT-29
|
EC50 |
|
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human HT-29 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
KB
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human KB cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182]
|
KB
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human KB cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631]
|
KB
|
IC50 |
> 5 μg/mL
Compound: Hederagenin
|
Cytotoxicity against human KB cells by colorimetric method
Cytotoxicity against human KB cells by colorimetric method
|
[PMID: 16038539]
|
KB
|
IC50 |
14.631 μM
Compound: Hederagenin
|
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human KB cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662]
|
KB
|
IC50 |
54.43 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
Antiproliferative activity against human KB cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
M14
|
IC50 |
|
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
Cytotoxicity against human M14 cells after 48 hrs by MTT assay
|
[PMID: 21954959]
|
MCF7
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MCF7 cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182]
|
MCF7
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631]
|
MCF7
|
EC50 |
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
MCF7
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
MCF7
|
EC50 |
|
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
Cytotoxicity against human MCF7 cells assessed as cell survival after 96 hrs by sulforhodamine B assay
|
[PMID: 26476750]
|
MCF7
|
IC50 |
39.389 μM
Compound: Hederagenin
|
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662]
|
MDA-MB-231
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by SRB assay
|
[PMID: 31718182]
|
MDA-MB-231
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by sulforhodamine B assay
|
[PMID: 29131631]
|
MDA-MB-231
|
IC50 |
36.609 μM
Compound: Hederagenin
|
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 28237662]
|
MKN-45
|
IC50 |
53.69 μM
Compound: alpha-hederagenin
|
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay
|
[PMID: 29040953]
|
NCI-H187
|
IC50 |
> 5 μg/mL
Compound: Hederagenin
|
Cytotoxicity against human NCI-H187 cells by colorimetric method
Cytotoxicity against human NCI-H187 cells by colorimetric method
|
[PMID: 16038539]
|
NCI-H1975
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells incubated for 72 hrs by MTS assay
|
[PMID: 31718182]
|
NCI-H1975
|
IC50 |
> 10 μM
Compound: Hederagenin
|
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
Antiproliferative activity against human NCI-H1975 cells harbouring EGFR L858R/T790M/C797S mutant incubated for 72 hrs by MTS assay
|
[PMID: 31718182]
|
NIH3T3
|
EC50 |
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
NIH3T3
|
EC50 |
> 30 μM
Compound: He; Hederagenin
|
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay
|
[PMID: 27017553]
|
Sf9
|
IC50 |
> 20 μM
Compound: Hederagenin
|
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo kinase assay
|
[PMID: 31718182]
|
Sf9
|
IC50 |
> 20 μM
Compound: Hederagenin
|
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M double mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo k
|
[PMID: 31718182]
|
Sf9
|
IC50 |
> 20 μM
Compound: Hederagenin
|
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
Inhibition of C-terminal His-tagged/ N-terminal GST-tagged recombinant human EGFR L858R/T790M/C797S mutant (668 to 1210 residues) expressed in a Baculovirus infected Sf9 cell expression system using poly-EY as substrate incubated for 30 mins by ADP-Glo ki
|
[PMID: 31718182]
|
SW-1736
|
EC50 |
|
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability after 96 hrs by SRB assay
|
[PMID: 30840925]
|
SW-1736
|
EC50 |
|
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
Cytotoxicity against human SW1736 cells assessed as reduction in cell viability incubated fro 96 hrs by SRB assay
|
[PMID: 29024910]
|
U-87MG ATCC
|
IC50 |
|
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
Cytotoxicity against human U87MG cells assessed as cell viability after 72 hrs by MTT assay
|
[PMID: 23992864]
|